Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBITDA: 2011-2024

Historic EBITDA for Niagen Bioscience (NAGE) over the last 12 years, with Dec 2024 value amounting to $7.7 million.

  • Niagen Bioscience's EBITDA rose 164.42% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 million, marking a year-over-year increase of 4218.57%. This contributed to the annual value of $7.7 million for FY2024, which is 237.99% up from last year.
  • Niagen Bioscience's EBITDA amounted to $7.7 million in FY2024, which was up 237.99% from -$5.6 million recorded in FY2023.
  • Niagen Bioscience's 5-year EBITDA high stood at $7.7 million for FY2024, and its period low was -$27.1 million during FY2021.
  • Its 3-year average for EBITDA is -$5.5 million, with a median of -$5.6 million in 2023.
  • As far as peak fluctuations go, Niagen Bioscience's EBITDA slumped by 36.36% in 2021, and later soared by 237.99% in 2024.
  • Over the past 5 years, Niagen Bioscience's EBITDA (Yearly) stood at -$19.9 million in 2020, then slumped by 36.36% to -$27.1 million in 2021, then spiked by 31.19% to -$18.6 million in 2022, then skyrocketed by 69.94% to -$5.6 million in 2023, then skyrocketed by 237.99% to $7.7 million in 2024.